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Introduction 
Oral potentially malignant disorders (PMD) are clinically recognisable mucosal 
abnormalities that share an increased risk of squamous cell carcinoma (SCC) 
development. Although comprising both localized lesions and more generalized 
conditions, the majority present clinically as oral leukoplakia at ventro-lateral tongue, 
floor of mouth and buccal mucosal sites1. Confusion and potential inaccuracy in using 
clinically descriptive terms such as leukoplakia to establish PMD diagnosis is an 
increasingly recognised problem, however2. In general, PMD are characterised 
microscopically by the presence of variably disorganised epithelial tissue change, 
varying from initial hyperplasia through to more significant dysplasia graded into 
increasingly severe categories; Table 11,3. Whilst it is generally assumed that the risk 
of malignant transformation (MT) is highest for more severely dysplastic tissue, this is 
not exclusively so and SCC can arise in lesions with minimal or even no pre-existing 
dysplastic change1,4.  
Risk assessment for individual patients presenting with PMD remains challenging in 
clinical practice. Whilst highly variable MT rates are quoted in the literature, systematic 
review has suggested an overall SCC development risk of 12% although this is mostly 
applicable to lesions exhibiting dysplasia5. As the natural history of PMD remains 
unpredictable, contemporaneous PMD management is based upon incision biopsy for 
provisional histological assessment and dysplasia grading followed by surgical 
excision to facilitate definitive diagnosis and treatment of lesions deemed ‘high-
risk’3,6,7.  
Whilst this treatment approach has proved both reliable and efficacious3, the authors 
of this paper remain concerned about those clinically suspicious oral lesions initially 
deemed innocuous by incision biopsy that subsequently progress to invasive SCC. 
This can only be considered a significant and potentially life-threatening failure in PMD 
management. Although for many years an alarming yet anecdotal observation, this 
scenario was specifically confirmed in a paper by Goodson et al4 which demonstrated 
that the majority of previously recognised precursor lesions progressing to SCC 
showed no histopathological evidence of dysplasia on incision biopsy, with 23 out of 
the 58 transforming lesions (40%) exhibiting only hyperkeratosis or lichenoid 
inflammation (LI). 
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How significant then should one regard a histopathological diagnosis of hyperplasia, 
hyperkeratosis or LI during PMD diagnosis and management? Strictly speaking, 
hyperplasia refers to epithelial thickening caused by an increase in the number of 
component cells due to an enhanced proliferation rate, whilst hyperkeratosis describes 
the histological appearance resulting from excessive, superficial keratin accumulation. 
Often these occur concurrently, and may be caused by genetic, physiological, 
inflammatory or dysmaturation processes. Whilst reactive lesions are most common, 
and their aetiological factors can be recognized and addressed, clinical examination 
alone is inadequate to distinguish a benign, reactive process from early dysplastic 
change8. Figure 1 illustrates the clinical appearance of hyperkeratosis due to local 
frictional irritation and contrasts this with leukoplakia resulting from an underlying 
epithelial dysplasia. Adding to the diagnostic confusion are solitary oral lichenoid 
lesions (OLL), characterized by the presence of lichenoid inflammatory change 
subjacent to hyperplastic or dysplastic epithelium, and multi-focal white lesions 
exhibiting both verrucous epithelial hyperkeratosis and LI forming part of the spectrum 
of proliferative verrucous leukoplakia (PVL)9.  
In a previous study of 590 PMD patients undergoing standardised interventional 
treatment, we documented incision and excision biopsy diagnoses and compared the 
results with clinical outcome data to try to determine the reliability of pre-operative 
histopathological assessment7. Importantly, in 220 cases (36.1%) excision specimens 
had to be ‘up-graded’ from their initial incision biopsy diagnosis because of the 
identification of more severe dysplasia (n = 121, 19.9%) or SCC (n = 99, 16.2%)7. The 
specific aim of this current paper was to re-visit these original data, and to review the 
histopathology and clinical course for PMD lesions initially diagnosed as ‘simple’ 
hyperkeratosis.   
 
Method  
Initial Caldicott Approval from Newcastle University / Newcastle upon Tyne Hospitals 
NHS Foundation Trust facilitated anonymized, retrospective data collection from 
medical records, operating books and original pathology reports from PMD patients 
treated by CO2 laser surgery by one of the authors (PJT) at the Royal Victoria Infirmary 
Maxillofacial Unit between August 1996 and December 2014. Inclusion criteria 
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required new patients who presented with single-site disease. Recorded demographic 
and clinico-pathological data included: patient age and sex, appearance and site of 
presenting PMD, and both incision and excision biopsy histopathology diagnoses. 
Clinical outcome was classified as: disease free, presence of further PMD disease or 
MT at the study census date (31.12.14).  
All biopsies and CO2 laser surgeries were carried out by PJT, or colleagues working 
under direct supervision, to established guidelines and within 6 to 12 weeks of initial 
presentation to prevent the risk of disease progression. Formalin-fixed tissue 
specimens were assessed via standardized histopathology examination by specialist 
oral pathologists, using agreed diagnostic criteria, peer review and consensus grading. 
The World Health Organization (WHO) system was used and dysplasia classified as 
mild, moderate and severe or carcinoma-in-situ. Diagnoses of hyperkeratosis, LI, and 
PVL were made as appropriate10.  
The 590 PMD cohort database was used to identify all patients initially characterised 
by incision biopsy diagnosis as hyperkeratosis (with no evident dysplasia) and their 
detailed clinico-pathological profile reviewed.   
 
 
Results 
In total, 58 of the 590 PMD patient cohort (9.8%) met the study criteria: 17 (2.9%), 
comprising 9 male and 8 female patients with a mean age of 60.9 years, were 
diagnosed as hyperkeratosis following incision biopsy, with a further 41 patients 
(6.9%), 15 male and 26 female (mean age 59.4 years), designated as hyperkeratosis 
with additional features of LI; full demographic and definitive diagnostic data for these 
cases are listed in Tables 2 and 3. All lesions initially presented as leukoplakia, and 
their anatomical site origins are summarized in Table 4; hyperkeratosis was identified 
at ventro-lateral tongue and floor of mouth sites in 9 patients (52.9%), whilst buccal 
mucosa, labial commissure, alveolus and gingiva were more frequently the site of 
hyperkeratotic lesions with lichenoid inflammatory features (26 cases or 63.4%). 
By listing definitive histopathological diagnoses from surgical excision biopsies against 
their initial incision biopsy data, Table 5 demonstrates that only 7 of the 17 cases 
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(41.2%) of hyperkeratosis were subsequently confirmed, with 10 requiring up-grading 
to more significant disease including 5 dysplasia (29.4%) and 2 SCC (11.8%); 5 of the 
7 cases (71.4%) arose on the ventro-lateral tongue and the floor of the mouth. Table 
6 similarly highlights that 25 out of 41 hyperkeratosis with LI cases (61%) were 
confirmed upon definitive diagnosis, whilst 14 exhibited dysplasia or carcinoma-in-situ 
(34.1%) and 1 SCC (2.4%); 10 of the 15 (66.6%) arose at ventro-lateral tongue or floor 
of mouth sites.    
Table 7 summarizes clinical outcome data, showing that in total 44 patients (75.9%) 
were rendered disease free following laser treatment with only 3 instances of MT 
(5.2%), consistent with previous reports of treatment efficacy and similar for both 
categories of hyperkeratoses7,11. The only notable difference in outcome was the 
higher incidence of further PMD disease affecting 10 patients (24.4%) with lichenoid 
inflammatory lesions, compared to 1 (5.9%) with hyperkeratosis only.  
 
 
Discussion 
Oral carcinogenesis is a complex and multi-step process, based fundamentally upon 
an increase in cellular proliferation and tissue hyperplasia, resistance to growth 
inhibition and apoptosis, and ultimate progression towards an invasive and metastatic 
phenotype1. It seems clear from the results of this investigation that a diagnosis of 
hyperkeratosis or hyperplasia, taken from incision biopsy sampling of a clinically 
suspicious PMD lesion, cannot exclude progression to subsequent MT. This is a 
significant observation, particularly as ‘epithelial hyperkeratosis’ is known to be one of 
the commonest diagnoses made within specialist oral medicine practice8. Whilst it is 
recognised that dysplasia grading can be subjective and imprecise, and that non-
representative biopsies and a change in dysplasia severity over time may confound 
diagnostic accuracy, these factors alone are insufficient to explain the results of the 
58 standardized cases analysed in this paper in which initial biopsies clearly under-
estimated both severity and progress of existing PMD disease.  
It has been suggested that up to half of clinically apparent leukoplakias may not exhibit 
dysplasia on biopsy and are often diagnosed as ‘non-specific’ or ‘simple’ 
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hyperplasia12. SCC development from non-dysplastic leukoplakia or ‘benign’ 
hyperkeratosis has been reported before, albeit somewhat anecdotally in a number of 
studies, affecting between 2 to 30% of cases13. The dilemma for clinicians is whether 
such lesions represent the initial stage of a progressive dysmaturation process that 
inevitably leads to carcinogenesis. On the basis of the evidence presented in this 
study, this must be considered the most likely scenario, especially in the absence of 
clinically demonstrable external irritants. 
In general, optimal patient assessment and accurate PMD diagnoses require careful 
consideration of both clinical and histopathological data. There is no substitute for 
clinical experience, acumen and a high level of suspicion during individual lesion 
assessment, and detailed communication between clinicians and pathologists is 
mandatory to assimilate these data fully and inform management decisions13.  Despite 
inherent limitations, oral epithelial dysplasia grading remains the ‘reference’ 
investigation in contemporary patient management, and is one of very few agreed 
assessment tools in estimating MT risk6,12.  
Oral premalignant conditions are associated with a number of molecular alterations. 
Included in these are genetic changes associated with, amongst many others, 
chromosomes 3p and 9p (short arms). These sub cellular changes have the potential 
to act as relevant indicators/biomarkers when aligning histopathological changes, 
such as hyperkeratosis and hyperplasia, to long term outcomes and whether they 
reflect predictable changes toward a more aggressive endpoint.  
Changes on chromosome 3p, have been the focus of a number of studies involving 
PMLs. Interest has arisen due to their identification, not only in invasive SCCs but also 
within low grade lesions deemed at risk of progression14. Alterations (losses or 
additions) in as many as six regions of 3p have been demonstrated including the loss 
of the FHIT gene, proposed as a tumour suppressor gene, who loss is associated 
strongly with development and prognosis of head and neck cancers15.  The alterations 
in chromosome 3p loci have been shown to be shared not only between high grade 
oral dysplastic tissue and carcinoma, but also with low grade histologically altered 
tissues that subsequently progressed to higher grade lesions. These 6 regions of 
alterations have been shown to contain up to 141 genes of which 9 have identified 
tumour suppressor activity 14.  
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Similarly, chromosome 9p changes have also been associated with premalignant 
tissue such as leucoplakia.  Whilst the “journey” from non-malignant to malignant 
change has been difficult to confirm with confidence, the associations with the loss of 
genetic material (allelic loss) and loss of heterozygosity, are indicative of the likelihood 
of histologic progression from a premalignant status 16. 
A range of cyto/molecular changes have been associated with PMLs, including 
insertion or deletion of microsatellite base pairs (microsatellite Instability MSI), 
chromosomal aneuploidy e.g. trisomy of chromosome 9 (although a less certain 
prognostic indicator as once previously thought), increased telomerase activity, P53 
alterations, a possible role for mitochondrial DNA changes and epigenetic alterations 
such as hyper-methylation of key promoter regions 16. 
Which of these factors plays an upstream role and under which circumstances, is the 
focus of ongoing research, but it is clear that receiving a diagnosis of hyperplasia 
and/or hyperkeratosis, needs to be referenced against an activation of a range of sub 
cellular changes, in response to known risk factors, that may indicate further 
progression towards a more sinister outcome. 
Until the “biomarker” led indicators can help us with accurate prognostic indicators 
then patient observational studies such as this one, therefore, offers some of the best 
currently available insights into the natural history of PMD17.  
Despite the identification of significant dysplasia and occult SCC within presenting 
PMD in this study, it is encouraging to note that 75% of patients were disease free at 
the study census date; this observation is probably a testimony to the efficacy of 
interventional laser surgery, which has been demonstrated to improve diagnostic 
accuracy and deliver reliable PMD treatment7,11,18,19. There is probably no more 
important issue in PMD diagnosis and management, however, than the development 
of invasive SCC, and MT was seen in 3 patients (5.2%) during this study. Whilst the 
implications of SCC development can be devastating, we have previously 
demonstrated significant benefit, in terms of improved long-term prognosis and 
disease-free survival, when early invasive SCCs were fortuitously removed during the 
laser excision of PMD20. 
Despite controversies in diagnosis and terminology, up to 29% of PMD have been 
shown to exhibit features of LI or PVL on histopathological assessment, with such 
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lesions appearing primarily as leukoplakia on the ventro-lateral tongue, floor of mouth, 
labio-buccal mucosa and gingiva7,9. Whether OLL and PVL are discrete examples of 
PMD or represent a progressive disease continuum is unclear, but a high MT risk has 
been reported for both multi-focal PVL and isolated tongue OLL, usually in the 
absence of pre-existing dysplasia21.  
 
 
Conclusions 
A provisional diagnosis of hyperkeratosis or LI from incision biopsy sampling of a 
clinically suspicious PMD lesion is not an ‘innocent’ finding, and lesions should not be 
considered ‘benign’. Clinician experience and judgement, together with effective 
communication with specialist pathologists, remain fundamental for accurate 
assessment and effective management of newly presenting PMD. Formal excision 
biopsy of oral mucosal lesions is therefore recommended to facilitate both definitive 
diagnosis and effective treatment. 
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TABLES 
 
 
Table 1: Histopathological Classification of Epithelial Disorganisation in PMD 
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Grade Epithelial Disorganisation  
Hyperplasia Hyperkeratosis, Epithelial Thickening, Normal Maturation 
Mild Dysplasia Primarily Basal Cell Hyperplasia affecting Lower 1/3rd Epithelium  
Moderate Dysplasia Disordered Maturation spreading to Middle 1/3rd Epithelium 
Severe Dysplasia Disordered Maturation reaching Upper 1/3rd Epithelium 
Carcinoma-in-Situ Full Thickness Dysmaturation & Disorganisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Age, Sex, Site, Definitive Diagnoses & Outcome for PMD Patients 
initially diagnosed with ‘Hyperkeratosis’ (No = 17) 
 
Age Sex Lesion Site Definitive Diagnosis Clinical Outcome 
71 F Buccal Mucosa SCC Malignant Transformation 
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69 M Ventral Tongue SCC Malignant Transformation 
63 M Lateral Tongue Proliferative Verrucous Leukoplakia Disease Free 
65 M Floor of Mouth Mild Dysplasia Disease Free 
51 F Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Disease Free 
57 M Ventral Tongue Mild Dysplasia Disease Free 
57 M Palate Mild Dysplasia Disease Free 
58 M Labial Mucosa Hyperkeratosis Disease Free 
77 F Lateral Tongue Hyperkeratosis Disease Free 
59 F Palate Hyperkeratosis Further Disease 
62 M Ventral Tongue Hyperkeratosis Disease Free 
49 F Lateral Tongue Mild Dysplasia Disease Free 
56 M Floor of Mouth Hyperkeratosis Disease Free 
57 F Labial Commissure Hyperkeratosis Disease Free 
67 M Palate Hyperkeratosis Disease Free 
64 F Alveolus Proliferative Verrucous Leukoplakia Disease Free 
53 F Lateral Tongue Moderate Dysplasia Disease Free 
 
 
 
 
 
 
 
Table 3: Age, Sex, Site, Definitive Diagnoses & Outcome for PMD Patients 
initially diagnosed with ‘Hyperkeratosis + Lichenoid Inflammation’ (No = 41) 
 
Age Sex Lesion Site Definitive Diagnosis Clinical Outcome 
42 F Alveolus Hyperkeratosis + Lichenoid Inflammation Further Disease 
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65 M Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Disease Free 
44 M Lateral Tongue Severe Dysplasia Further Disease 
68 F Lateral Tongue SCC Malignant Transformation 
70 M Floor of Mouth Mild Dysplasia Disease Free 
43 M Floor of Mouth Mild Dysplasia Further Disease 
65 F Alveolus Hyperkeratosis + Lichenoid Inflammation Disease Free 
56 M Lateral Tongue Mild Dysplasia Disease Free 
62 F Ventral Tongue Moderate Dysplasia Disease Free 
73 F Lateral Tongue Hyperkeratosis + Lichenoid Inflammation Disease Free 
50 F Palate Hyperkeratosis + Lichenoid Inflammation Disease Free 
54 F Gingiva Hyperkeratosis + Lichenoid Inflammation Disease Free 
60 M Lateral Tongue Moderate Dysplasia Disease Free 
51 F Gingiva Hyperkeratosis + Lichenoid Inflammation Disease Free 
55 F Lateral Tongue Hyperkeratosis + Lichenoid Inflammation Disease Free 
74 F Gingiva Hyperkeratosis + Lichenoid Inflammation Disease Free 
78 F Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Disease Free 
55 F Lateral Tongue Mild Dysplasia Disease Free 
65 F Gingiva Hyperkeratosis + Lichenoid Inflammation Disease Free 
49 M Labial Commissure Mild Dysplasia Further Disease 
57 F Gingiva Hyperkeratosis + Lichenoid Inflammation Further Disease 
62 M Labial Commissure Chronic Hyperplastic Candidosis Disease Free 
51 M Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Further Disease 
53 F Gingiva Hyperkeratosis + Lichenoid Inflammation Disease Free 
52 F Palate Mild Dysplasia Disease Free 
63 F Gingiva Hyperkeratosis + Lichenoid Inflammation Disease Free 
70 M Buccal Mucosa Mild Dysplasia Further Disease 
83 F Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Further Disease 
41 F Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Disease Free 
42 M Floor of Mouth Mild Dysplasia Disease Free 
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63 F Alveolus Hyperkeratosis + Lichenoid Inflammation Further Disease 
60 F Alveolus Hyperkeratosis + Lichenoid Inflammation Further Disease 
79 F Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Disease Free 
64 F Buccal Mucosa Hyperkeratosis + Lichenoid Inflammation Disease Free 
60 F Alveolus Hyperkeratosis + Lichenoid Inflammation Disease Free 
61 F Alveolus Hyperkeratosis + Lichenoid Inflammation Disease Free 
50 F Floor of Mouth Hyperkeratosis + Lichenoid Inflammation Disease Free 
58 M Lateral Tongue Carcinoma-in-Situ Disease Free 
52 M Labial Commissure Hyperkeratosis + Lichenoid Inflammation Disease Free 
60 M Buccal Mucosa Mild Dysplasia Disease Free 
77 M Buccal Mucosa Mild Dysplasia Disease Free 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Site of Presenting Lesion 
Anatomical Site Hyperkeratosis 
 No (%) 
Hyperkeratosis + 
Lichenoid Inflammation 
No (%) 
Buccal/Labial Commissure 4 (23.5%) 13 (31.7%) 
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Ventral Tongue/Floor of Mouth 5 (29.4%) 5 (12.2%) 
Lateral Tongue 4 (23.5%) 8 (19.5%) 
Palate 3 (17.6%) 2 (4.9%) 
Alveolus/Gingiva 1 (5.9%) 13 (31.7%) 
TOTAL 17 (100%) 41 (100%) 
 
 
 
Table 5: Definitive Histopathological Diagnoses for Hyperkeratosis following 
Laser Excision Biopsy (Total No = 17) 
 
Definitive Diagnosis Number (%) 
 
Hyperkeratosis 
Hyperkeratosis + Lichenoid Inflammation   
PVL 
Mild Dysplasia 
Moderate Dysplasia 
Severe Dysplasia 
Carcinoma-in-Situ 
SCC                                  
 
 
7 (41.1%) 
1 (5.9%) 
2 (11.8%) 
4 (23.5%) 
1 (5.9%) 
0 (0%) 
0 (0%) 
2 (11.8%) 
 
 
 
Table 6: Definitive Histopathological Diagnoses for Hyperkeratosis + Lichenoid 
Inflammation following Laser Excision Biopsy (Total No = 41) 
 
Definitive Diagnosis Number (%) 
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Chronic Hyperplastic Candidosis 
Hyperkeratosis + Lichenoid Inflammation   
PVL 
Mild Dysplasia 
Moderate Dysplasia 
Severe Dysplasia 
Carcinoma-in-Situ 
SCC                                
 
 
 1 (2.4%) 
25 (61.0%) 
 0 (0%) 
10 (24.4%) 
 2 (4.9%) 
 1 (2.4%) 
 1 (2.4%) 
 1 (2.4%) 
 
 
 
 
Table 7: Clinical Outcome Post-Laser Excision (Study Census Date 31.12.14) 
 
Clinical Outcome Hyperkeratosis 
Number (%) 
Hyperkeratosis + Lichenoid Inflammation 
Number (%) 
Disease Free 14 (82.3%) 30 (73.2%) 
Further Disease 1  (5.9%) 10 (24.4%) 
Malignant Transformation  2 (11.8%) 1  (2.4%) 
 
 
 
 
FIGURES 
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A 
 
B 
Figure 1: White mucosal lesions arising on the left buccal mucosa, showing (A) classic 
frictional hyperkeratosis secondary to repetitive occlusal irritation, and (B) leukoplakia 
which exhibited moderate dysplasia on incision biopsy. 
